Kynmobi Generic Name & Formulations
Kynmobi Dosage and Administration
See full labeling. Consider premedication with trimethobenzamide (300mg 3 times daily) starting 3 days prior to apomorphine initiation. Administer sublingually. Supervise 1st dose (monitor BP and pulse). Initially 10mg; if tolerated and effective, give up to max 5 times daily (as needed basis). If insufficient response, increase by 5mg increments and continued generally within 3 days, then reevaluate. Usual range: 10–30mg/dose. Separate doses by at least 2hrs. Max 30mg/single dose.
Kynmobi Boxed Warnings
Nausea/vomiting: consider pretreatment with antiemetic (trimethobenzamide) for up to 2 months (see Adult dosing). Sleep disorders (discontinue if significant daytime sleepiness occurs). Hallucinations/psychosis. Impulse control/compulsive behaviors; consider dose reduction or discontinue if urges develop. History of hypotension. Cardiovascular disease. Proarrhythmic conditions (eg, hypokalemia, hypomagnesemia, bradycardia, congenital QT prolongation). Sulfite allergy. Asthma. Severe renal impairment or ESRD: avoid. Severe hepatic impairment: avoid. Elderly. Pregnancy. Nursing mothers.
Kynmobi Adverse Reactions
Kynmobi Clinical Trials
Kynmobi Patient Counseling